Naxitamab Clinical Trials
7 recruitingDrug
Phase 26Phase 13
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Metastatic Triple-negative Breast Cancer
M.D. Anderson Cancer Center31 enrolled1 locationNCT07011654
Recruiting
Phase 2
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Neuroblastoma
Giselle Sholler98 enrolled12 locationsNCT06540963
Recruiting
Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma
Giselle Sholler93 enrolled23 locationsNCT05489887
Recruiting
Phase 2
Quadruple Immunotherapy for Neuroblastoma
Neuroblastoma Recurrent
Hong Kong Children's Hospital29 enrolled1 locationNCT05754684
Recruiting
Phase 1
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
NeuroblastomaRefractory NeuroblastomaRelapsed Neuroblastoma+1 more
Steven DuBois, MD18 enrolled2 locationsNCT07027748
Recruiting
Phase 1Phase 2
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
Margaret Gatti-Mays42 enrolled1 locationNCT06026657
Recruiting
Phase 2
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
Ewing Sarcoma
Anna Raciborska24 enrolled2 locationsNCT05968768